Vertex
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2009-01-01
- Employees
- 1.5K
- Market Cap
- -
- Website
- http://www.vertex-med.com
- Introduction
Vertex, Inc. engages in the provision of tax compliance software solutions. The firm offers comprehensive solutions that automate end-to-end indirect tax processes for enterprises and mid-market companies with complex tax transactions. Its software enables tax determination, data management, compliance and reporting, and document management. The company was founded by Ray Westphal and Antoinette Westphal in 1978 and is headquartered in King of Prussia, PA.
Royalty Pharma Secures 99.9% Shareholder Approval for $1.1 Billion External Manager Acquisition
Royalty Pharma shareholders have overwhelmingly approved the acquisition of its external manager, with 99.9% voting in favor at the company's 2025 Annual General Meeting.
Takeda Spotlights Three Late-Stage Readouts as Potential "Inflection Point" Amid Vyvanse Generic Competition
Takeda Pharmaceutical is positioning three upcoming late-stage clinical trial readouts as a strategic "inflection point" to offset revenue losses from Vyvanse's generic competition.
Calidi Biotherapeutics Appoints Eric Poma as New CEO to Advance Novel Cancer Virotherapy Platform
Calidi Biotherapeutics has appointed Eric Poma, Ph.D., as its new CEO effective April 22, 2025, succeeding Allan Camaisa who will continue to serve on the company's Board of Directors.
Orphan Drug Market Growth Slowing but Remains Strategic Priority for Pharma
Orphan drug sales reached $168 billion globally in 2023, with growth expected to moderate to just under 10% annually through 2028, according to Evaluate's latest report.
Lexicon's Non-Opioid Pain Drug Pilavapadin Misses Primary Endpoint in Phase IIb Diabetic Neuropathy Trial
Lexicon Pharmaceuticals' non-opioid painkiller pilavapadin failed to achieve statistical significance versus placebo in Phase IIb RELIEF-DPN-1 trial for diabetic neuropathy pain.
NHS England Approves Gene-Editing Therapy Casgevy for Severe Sickle Cell Disease
NHS England approves Casgevy, a gene-editing therapy, for treating severe sickle cell disease in eligible patients aged 12 and over.
FDA Approves New Therapies for Hemophilia, Colorectal Cancer, and Cystic Fibrosis
The FDA approved Alhemo (concizumab) from Novo Nordisk for hemophilia A and B with inhibitors, offering a once-daily subcutaneous option.
GSK's Ovarian Cancer Drug Combination Shows Promise; Novo Nordisk's Obesity Drug Trial Disappoints
GSK's cancer drug combination achieved primary endpoints in ovarian cancer trials, marking a significant advancement in treatment options, though some secondary goals were unmet.
Pharma Share Moves of 2024: Lilly and Vertex Rise, Pfizer and Merck Decline
Eli Lilly's shares surged by 37% YTD, driven by the success of Zepbound for weight loss and advancements in its Alzheimer's treatment, Kisunla.
Vertex Raises 2024 Revenue Guidance Amidst Promising Pipeline Advancements
Vertex Pharmaceuticals increased its full-year product revenue guidance to $10.8-$10.9 billion, driven by strong performance of TRIKAFTA/KAFTRIO and anticipated CASGEVY launches.